# Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

> **NCT05026983** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 35 (estimated)

## Conditions studied

- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Melanoma
- Pathologic Stage IV Cutaneous Melanoma AJCC v8

## Interventions

- **DRUG:** Binimetinib
- **DRUG:** Encorafenib
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT05026983
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-27
- **Primary completion:** 2027-02-02
- **Final completion:** 2027-02-02
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05026983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05026983, "Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05026983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*